16 patents
Utility
Glutarimides for medical treatment
31 Oct 23
The present invention provides selected glutarimides which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins.
Roger Norcross, Annick Goergler, Philipp Schmid, Fabian Dey, Eric Andre Kusznir
Filed: 4 Mar 20
Utility
Dihydrobenzimidazolones for medical treatment
17 Oct 23
The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins.
Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
Filed: 14 Jan 22
Utility
Cereblon binders for the degradation of ikaros
12 Sep 23
James A. Henderson, Gesine Kerstin Veits, Minsheng He, Christopher G. Nasveschuk, Andrew J. Phillips, Andrew Charles Good
Filed: 24 Sep 20
Utility
Compounds for targeted degradation of BRD9
4 Jul 23
Christopher G. Nasveschuk, Rhamy Zeid, Ning Yin, Katrina L. Jackson, Gesine Kerstin Veits, Moses Moustakim, Jeremy L. Yap
Filed: 2 Dec 21
Utility
Spirocyclic compounds
11 Apr 23
The present invention provides compounds and intermediates.
Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
Filed: 24 Nov 20
Utility
Spirocyclic compounds
21 Feb 23
The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation.
Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
Filed: 16 Oct 20
Utility
Degraders and Degrons for targeted protein degradation
13 Dec 22
Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
Filed: 14 May 20
Utility
N/O-linked Degrons and Degronimers for protein degradation
4 Oct 22
This invention provides Degronimers that have E3 Ubiquitin Ligase targeting moieties (Degrons) that can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Martin Duplessis, Chi-Li Chen
Filed: 19 Dec 19
Utility
Tricyclic degraders of Ikaros and Aiolos
9 Aug 22
Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.
James A. Henderson, Minsheng He, Andrew Charles Good, Andrew John Phillips
Filed: 11 Oct 21
Utility
Dihydroquinolinones for medical treatment
2 Aug 22
The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins.
Roger Norcross, Adrian Britschgi, Fabian Dey, Annick Goergler, Eric Andre Kusznir, Moreno Attilio Wichert
Filed: 4 Mar 20
Utility
Dihydrobenzimidazolones for medical treatment
22 Feb 22
The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins.
Roger Norcross, Annick Goergler, Fabian Dey, Eric Andre Kusznir
Filed: 4 Mar 20
Utility
Spirocyclic degronimers for target protein degradation
30 Nov 21
This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
Filed: 22 May 20
Utility
Heterocyclic degronimers for target protein degradation
2 Feb 21
This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
Filed: 11 May 20
Utility
C3-carbon linked glutarimide degronimers for target protein degradation
30 Nov 20
This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
Filed: 8 Nov 18
Utility
Spirocyclic degronimers for target protein degradation
25 May 20
This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
Filed: 8 Nov 18
Utility
Heterocyclic degronimers for target protein degradation
11 May 20
This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.
Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
Filed: 8 Nov 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first